Abstract: Compositions and methods for improved delivery of mRNA into eukaryotic cells using histidine-lysine (HK) peptide polymers are disclosed. The branched polymers comprising four short peptide branches linked to a three-lysine amino acid core. The peptide branches consist of histidine and lysine amino acids, in different configurations, and they can vary in their location on the lysine core.

Abstract: The invention provides a branched copolymer for the treatment of bacterial, fungal, and viral infections. The branched copolymer is characterized as having (i) at least 10 amino acids, (ii) at least 10% of the amino acids are histidine, (iii) at least 10% of the amino acids are non-histidine, (iv) said branched polymer comprising one or more backbones, (v) one or more terminal branches, and (vi) optionally, one or more non-terminal branches.

Abstract: The invention provides a pharmaceutical agent delivery composition comprising: (i) a transport polymer comprising a linear or branched peptide having from about 10 to about 300 amino acid residues, having from about 5 to 100% histidine residues, and optionally having from 0 to about 95% non-histidine amino acid residues; (ii) at least one pharmaceutical agent; and optionally (iii) one or more intracellular delivery components in association with the transport polymer. The invention also provides methods for using such composition to deliver the pharmaceutical agent to the interior of cells.

Abstract: The invention provides a branched transport polymer characterized as having at least 10 amino acids and a ratio of histidine to non-histidine amino acids greater than 1.5, said branched transport polymer comprising one or more backbones, one or more terminal branches, and optionally, one or more non-terminal branches. The branched transport polymer may be associated with a pharmaceutical agent to form a pharmaceutical agent delivery composition useful for in vivo therapies based on local injection.

Abstract: The invention provides a branched transport polymer characterized as having at least 10 amino acids and a ratio of histidine to non-histidine amino acids greater than 1.5, said branched transport polymer comprising one or more backbones, one or more terminal branches, and optionally, one or more non-terminal branches. The branched transport polymer may be associated with a pharmaceutical agent to form a pharmaceutical agent delivery composition useful for in vivo therapies based on local injection.

Abstract: The invention provides a pharmaceutical agent delivery composition comprising: (i) a transport polymer comprising a linear or branched peptide having from about 10 to about 300 amino acid residues, having from about 5 to 100% histidine residues, and optionally having from 0 to about 95% non-histidine amino acid residues; (ii) at least one pharmaceutical agent; and optionally (iii) one or more intracellular delivery components in association with the transport polymer. The invention also provides methods for using such composition to deliver the pharmaceutical agent to the interior of cells.

Abstract: Carrier complexes comprising nucleic acid encoding an anti-angiogenic gene or peptide and optionally a further nucleic acid encoding a tumor suppressor protein are described. When administered to a subject bearing a tumor, the complexes can inhibit growth of the tumor.

Abstract: Carrier complexes comprising DNA encoding an anti-angiogenic gene or peptide and optionally a further DNA encoding a tumor suppressor protein are described. When administered to a subject bearing a tumor, the complexes can inhibit growth of the tumor.